Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Medical - Pharmaceuticals

Healthcare
$9.01 +4.29%

+$0.62 today

Market cap
$584.94M
Beta
0.01
P/E (TTM)
-4.0
EPS (TTM)
-$3.73
52W Low $5.68High $16.74

Volume 1.06M

Average 0.99M

Returns on capital

Cullinan Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-53.8%

avg -2.3%

ROIC

-58.7%

avg -27.9%

ROA

-49.0%

avg -23.5%

Analysis

ROA is currently the strongest return metric at -49.0% versus its period average of -23.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Nadim Ahmed

President, Chief Executive Officer & DirectorUSD 1.17M58390.80K0.64%

Jeffrey Jones

Chief Medical OfficerUSD 801.78K55——

Mary Kay Fenton

Chief Financial OfficerUSD 768.26K62127.92K0.21%

Patrick A. Baeuerle

Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory BoardUSD 763.73K68——

Corinne Savill

Chief Business Officer—67——

Jennifer Michaelson

Chief Scientific Officer—5975.18K0.12%

Steve Andre

Chief Human Resources Officer————

Jacquelyn L. Sumer

Chief Legal Officer, Chief Compliance Officer & Corporate Secretary—48130.56K0.21%

Rose Weldon

Senior Vice President of Corporate Affairs————

Nicholas Smith

Head of Investor Relations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 5, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

29

$2.56M

Net Transaction Value

−$2.56M

Net selling

Most Active

Michaelson Jennifer

19 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 5, 26

Michaelson Jennifer

Direct

Sell$49.4K
Sep 8, 26

Michaelson Jennifer

Direct

Sell$172.6K
Aug 13, 26

Michaelson Jennifer

Direct

Sell$607.8K
Jul 6, 26

Michaelson Jennifer

Direct

Sell$142.6K
May 5, 26

Michaelson Jennifer

Direct

Sell$113.9K
May 5, 26

Michaelson Jennifer

Direct

Sell$3.1K
Mar 5, 26

Michaelson Jennifer

Direct

Sell$125.4K
Feb 25, 26

Michaelson Jennifer

Direct

Sell$25.2K
Feb 24, 26

AHMED NADIM

Direct

Sell$195.6K
Feb 24, 26

Michaelson Jennifer

Direct

Sell$52.1K

1–10 of 29

Summary

Insiders reported 0 buys worth $0.00 and 29 sells worth $2.56M over the last 12 months. That adds up to net selling of $2.56M. Michaelson Jennifer was the most active insider with 19 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
N/A6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Cullinan Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CGEM's management, answered from reported figures.

Who manages CGEM?

Cullinan Therapeutics, Inc. (CGEM) lists 10 active executives. The top listed executive is Corinne Savill, Chief Business Officer.

Are CGEM insiders buying or selling?

Recent insider activity shows net buying of $64.05M.